Literature DB >> 31143992

Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis : Comment on "Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis".

S Noe1, H Jaeger2, E Wolf3.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31143992     DOI： 10.1007/s00198-019-05024-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  14 in total

1.  Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

Authors:  Josep M Llibre; Chien-Ching Hung; Cynthia Brinson; Francesco Castelli; Pierre-Marie Girard; Lesley P Kahl; Elizabeth A Blair; Kostas Angelis; Brian Wynne; Kati Vandermeulen; Mark Underwood; Kim Smith; Martin Gartland; Michael Aboud
Journal:  Lancet       Date:  2018-01-06       Impact factor: 79.321

Review 2.  The protease inhibitors and HIV-associated bone loss.

Authors:  Caitlin A Moran; M Neale Weitzmann; Ighovwerha Ofotokun
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

3.  Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

Authors:  Pedro Cahn; Juan Sierra Madero; José Ramón Arribas; Andrea Antinori; Roberto Ortiz; Amanda E Clarke; Chien-Ching Hung; Jürgen K Rockstroh; Pierre-Marie Girard; Jörg Sievers; Choy Man; Alexander Currie; Mark Underwood; Allan R Tenorio; Keith Pappa; Brian Wynne; Anna Fettiplace; Martin Gartland; Michael Aboud; Kimberly Smith
Journal:  Lancet       Date:  2018-11-09       Impact factor: 79.321

4.  Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.

Authors:  Massimiliano Fabbiani; Roberta Gagliardini; Nicoletta Ciccarelli; Eugenia Quiros Roldan; Alessandra Latini; Gabriella d'Ettorre; Andrea Antinori; Antonella Castagna; Giancarlo Orofino; Daniela Francisci; Pierangelo Chinello; Giordano Madeddu; Pierfrancesco Grima; Stefano Rusconi; Barbara Del Pin; Francesca Lombardi; Alessandro D'Avino; Emanuele Focà; Manuela Colafigli; Roberto Cauda; Simona Di Giambenedetto; Andrea De Luca
Journal:  J Antimicrob Chemother       Date:  2018-07-01       Impact factor: 5.790

5.  Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis.

Authors:  E Biver; A Calmy; B Aubry-Rozier; M Birkhäuser; H A Bischoff-Ferrari; S Ferrari; D Frey; R W Kressig; O Lamy; K Lippuner; N Suhm; C Meier
Journal:  Osteoporos Int       Date:  2019-01-02       Impact factor: 4.507

6.  Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.

Authors:  S S L Goh; P S M Lai; A T B Tan; S Ponnampalavanar
Journal:  Osteoporos Int       Date:  2017-11-20       Impact factor: 4.507

7.  Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults.

Authors:  François Raffi; Chloe Orkin; Amanda Clarke; Laurence Slama; Joel Gallant; Eric Daar; Keith Henry; Jorge Santana-Bagur; David K Stein; Nicholaos Bellos; Anthony Scarsella; Mingjin Yan; Michael E Abram; Andrew Cheng; Martin S Rhee
Journal:  J Acquir Immune Defic Syndr       Date:  2017-06-01       Impact factor: 3.731

8.  Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.

Authors:  Grace A McComsey; Sergio Lupo; David Parks; Mónica Coronado Poggio; Joseph De Wet; Lesley P Kahl; Kostas Angelis; Brian Wynne; Kati Vandermeulen; Martin Gartland; Michael Cupo; Michael Aboud
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

9.  Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?

Authors:  Andrew Hill; Sophie L Hughes; Dzintars Gotham; Anton L Pozniak
Journal:  J Virus Erad       Date:  2018-04-01

10.  Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.

Authors:  Chloe Orkin; Jean-Michel Molina; Eugenia Negredo; José R Arribas; Joseph Gathe; Joseph J Eron; Erika Van Landuyt; Erkki Lathouwers; Veerle Hufkens; Romana Petrovic; Simon Vanveggel; Magda Opsomer
Journal:  Lancet HIV       Date:  2017-10-06       Impact factor: 12.767
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.